Document is current
Any future updates will be listed below
-
Authors
Liu, Chao
Hu, Yun-hui
Han, Yu
Wang, Yong-bin
Zhang, Yan
Zhang, Xiao-qun
He, Duo-fen
Ren, Hong-mei
Liu, Yu-kai
Wang, Hong-yong
Tan, Tao
Lin, Pei-hui
Li, Hai-chang
Rovin, Brad H.
Ma, Jian-jie
Zeng, Chun-yu
- License Information
-
More Information
Article History
Received: 15 January 2020
Accepted: 15 April 2020
First Online: 18 May 2020
Competing interests
: JJM and TT have an equity interest in TRIM-edicine, Inc., which develops rhMG53 for the treatment of human diseases. Patents on the use of MG53 are held by Rutgers University—Robert Wood Johnson Medical School.
